Trial Profile
Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Entecavir (Primary) ; Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- Acronyms HBRN IT Adult
- 29 Jun 2018 Status changed to discontinued.
- 29 Jun 2018 Status changed to discontinued.
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases